Company
New York
Every investor coverage indicates participated in a round Columbia University raised.
Companies Columbia University acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Dr Jeffrey Ascherman | Chief of the Division of Plastic Surgery (former) | GBS Ventures (Mon 26 Sep 2016), GBS Ventures (Tue 20 Oct 2015) |
Stories naming Columbia University. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
An exclusive interview with founder Sonia Kaurah discloses the culturally focused mental health platform's previously unreported $500,000 pre-seed round, backed by crowdfunding and angels, as the company relocates from London to Melbourne.
New Zealand biotech Amaroq Therapeutics reported early progress toward clinical trials and appointed four leading scientists to its scientific advisory board, strengthening its lncRNA cancer therapy programme.
AfterWork Ventures explains why it joined SwingVision's $2 million seed round led by Tennis Australia's Wildcard Ventures, alongside Roddick, Blake and the MyFitnessPal co-founders; the app brings pro-grade tennis analytics to amateurs.
Also Startup Daily
Blackbird's investment note explains why it co-led cyber intelligence startup Cyble's US$4 million seed round with Spider Capital, describing the dark web monitoring product, its founders, and its Y Combinator background.
AirXpanders shared new clinical data for its AeroForm breast reconstruction device at a major plastic surgery meeting, showing faster expansion times, and an Australian study author received a best-paper award.
AirXpanders reported positive results from its XPAND pivotal trial of the AeroForm tissue expander at a major plastic surgery meeting, showing faster expansion than saline devices, as it seeks US FDA clearance.
AirXpanders' needle-free breast-reconstruction device is showcased at a major American plastic surgery conference, with trial results presented; the ASX-listed company awaits a US regulatory decision.
Also GBS Ventures·GBS Ventures